Limited contribution of IL-36 versus IL-1 and TNF pathways in host response to mycobacterial infection

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Segueni, Noria ^a,b   Vigne, Solenne ^c,d   Palmer, Gaby ^c,d   Bourigault, Marie Laure ^a,b   Olleros, Maria L ^d   Vesin, Dominique ^d   Garcia, Irene ^d   Ryffel, Bernhard ^a,b,e   Quesniaux, Valérie F J ^a,b   Gabay, Cem ^c,d  

^a CNRS   (France)

^b UNIVERSITÉ D'ORLÉANS   (France)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^e UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

CXCL1 CHEMOKINE; CYTOKINE; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 36 RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; INTERLEUKIN 1; INTERLEUKIN-36, MOUSE; TUMOR NECROSIS FACTOR;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL CLEARANCE; BOVINE TUBERCULOSIS; CONTROLLED STUDY; IMMUNE RESPONSE; INFECTION CONTROL; INFECTION SENSITIVITY; LUNG PARENCHYMA; MOUSE; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SURVIVAL RATE; WILD TYPE; ANIMAL; C57BL MOUSE; HOST PATHOGEN INTERACTION; KNOCKOUT MOUSE; METABOLISM; MYCOBACTERIOSIS;

BACTERIA (MICROORGANISMS); MUS; MYCOBACTERIUM TUBERCULOSIS;

ANIMALS; HOST-PATHOGEN INTERACTIONS; INTERLEUKIN-1; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYCOBACTERIUM INFECTIONS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84929104232     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0126058     Document Type: Article

References (43)

1. Towne JE, Renshaw BR, Douangpanya J, Lipsky BP, Shen M, et al. Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36alpha, IL-36beta, and IL-36gamma) or antagonist (IL-36Ra) activity. J Biol Chem. 2011; 286: 42594-42602. doi: 10.1074/jbc.M111.267922 PMID: 21965679
2. Vigne S, Palmer G, Lamacchia C, Martin P, Talabot-Ayer D, et al. IL-36R ligands are potent regulators of dendritic and T cells. Blood. 2011; 118: 5813-5823. doi: 10.1182/blood-2011-05-356873 PMID: 21860022
3. Mutamba S, Allison A, Mahida Y, Barrow P, Foster N. Expression of IL-1Rrp2 by human myelomonocytic cells is unique to DCs and facilitates DC maturation by IL-1F8 and IL-1F9. Eur J Immunol. 2012; 42:607-617. doi: 10.1002/eji.201142035 PMID: 22144259
4. Foster AM, Baliwag J, Chen CS, Guzman AM, Stoll SW, et al. IL-36 promotes myeloid cell infiltration, activation, and inflammatory activity in skin. J Immunol. 2014; 192: 6053-6061. doi: 10.4049/jimmunol.1301481 PMID: 24829417
5. Vigne S, Palmer G, Martin P, Lamacchia C, Strebel D, et al. IL-36 signaling amplifies Th1 responses by enhancing proliferation and Th1 polarization of naive CD4+ T cells. Blood. 2012; 120: 3478-3487. doi: 10.1182/blood-2012-06-439026 PMID: 22968459
6. Dye C, Watt CJ, Bleed DM, Hosseini SM, Raviglione MC. Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. JAMA. 2005; 293: 2767-2775. PMID: 15941807
7. Dye C, Williams BG. The population dynamics and control of tuberculosis. Science.2010; 328: 856-861. doi: 10.1126/science.1185449 PMID: 20466923
8. Flynn JL, Chan J. Immunology of tuberculosis. Annu Rev Immunol. 2001; 19: 93-129. PMID: 11244032
9. Flynn JL. Immunology of tuberculosis and implications in vaccine development. Tuberculosis (Edinb). 2004; 84: 93-101. PMID: 14670350
10. North RJ, Jung YJ. Immunity to tuberculosis. Annu Rev Immunol. 2004; 22: 599-623. PMID: 15032590
11. Korbel DS, Schneider BE, Schaible UE. Innate immunity in tuberculosis: myths and truth. Microbes Infect. 2008; 10: 995-1004. doi: 10.1016/j.micinf.2008.07.039 PMID: 18762264
12. Mishra BB, Rathinam VA, Martens GW, Martinot AJ, Kornfeld H, et al. Nitric oxide controls the immunopathology of tuberculosis by inhibiting NLRP3 inflammasome-dependent processing of IL-1beta. Nat Immunol. 2013; 14: 52-60. doi: 10.1038/ni.2474 PMID: 23160153
13. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001; 345: 1098-1104. PMID: 11596589
14. Keane J. TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology (Oxford). 2005; 44: 714-720. PMID: 15741198
15. Mohan AK, Cote TR, Siegel JN, Braun MM. Infectious complications of biologic treatments of rheumatoid arthritis. Curr Opin Rheumatol. 2003; 15: 179-184. PMID: 12707568
16. Mohan VP, Scanga CA, Yu K, Scott HM, Tanaka KE, et al. Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect Immun. 2001; 69: 1847-1855. PMID: 11179363
17. Sugawara I, Yamada H, Hua S, Mizuno S. Role of interleukin (IL)-1 type 1 receptor in mycobacterial infection. Microbiol Immunol. 2001; 45: 743-750. PMID: 11791667
18. Juffermans NP, Florquin S, Camoglio L, Verbon A, Kolk AH, et al. Interleukin-1 signaling is essential for host defense during murine pulmonary tuberculosis. J Infect Dis. 2000; 182: 902-908. PMID: 10950787
19. Yamada H, Mizumo S, Horai R, Iwakura Y, Sugawara I. Protective role of interleukin-1 in mycobacterial infection in IL-1 alpha/beta double-knockout mice. Lab Invest. 2000; 80: 759-767. PMID: 10830786
20. Fremond CM, Togbe D, Doz E, Rose S, Vasseur V, et al. IL-1 receptor-mediated signal is an essential component of MyD88-dependent innate response to Mycobacterium tuberculosis infection. J Immunol. 2007; 179: 1178-1189. PMID: 17617611
21. Master SS, Rampini SK, Davis AS, Keller C, Ehlers S, et al. Mycobacterium tuberculosis prevents inflammasome activation. Cell Host Microbe. 2008; 3: 224-232. doi: 10.1016/j.chom.2008.03.003 PMID: 18407066
22. Mayer-Barber KD, Barber DL, Shenderov K, White SD, Wilson MS, et al. Caspase-1 independent IL-1beta production is critical for host resistance to mycobacterium tuberculosis and does not require TLR signaling in vivo. J Immunol. 2010; 184: 3326-3330. doi: 10.4049/jimmunol.0904189 PMID: 20200276
23. Mayer-Barber KD, Andrade BB, Barber DL, Hieny S, Feng CG, et al. Innate and adaptive interferons suppress IL-1alpha and IL-1beta production by distinct pulmonary myeloid subsets during Mycobacterium tuberculosis infection. Immunity. 2011; 35: 1023-1034. doi: 10.1016/j.immuni.2011.12.002 PMID: 22195750
24. Bourigault ML, Segueni N, Rose S, Court N, Vacher R, et al. Relative contribution of IL-1α, IL-1β and TNF to the host response to Mycobacterium tuberculosis and attenuated M. bovis BCG. Immunity, Inflammat & Disease. 2013; 1: 47-62.
25. Gabay C, Towne J. Regulation and function of interleukin-36 cytokines in homeostasis and pathological conditions. J Leukoc Biol. 2015; 97: 645-652. PMID: 25673295
26. Blumberg H, Dinh H, Trueblood ES, Pretorius J, Kugler D, et al. Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation. J Exp Med. 2007; 204: 2603-2614. PMID: 17908936
27. Labow M, Shuster D, Zetterstrom M, Nunes P, Terry R, et al. Absence of IL-1 signaling and reduced inflammatory response in IL-1 type I receptor-deficient mice. J Immunol. 1997; 159: 2452-2461. PMID: 9278338
28. Marino MW, Dunn A, Grail D, Inglese M, Noguchi Y, et al. Characterization of tumor necrosis factor-deficient mice. Proc Natl Acad Sci U S A. 1997; 94: 8093-8098. PMID: 9223320
29. Lamacchia C, Palmer G, Gabay C. Discrimination of C57BL/6J Rj and 129S2/SvPasCrl inbred mouse strains by use of simple sequence length polymorphisms. J Am Assoc Lab Anim Sci. 2007; 46: 21-24. PMID: 17994669
30. Olleros ML, Vesin D, Fotio AL, Santiago-Raber ML, Tauzin S, et al. Soluble TNF, but not membrane TNF, is critical in LPS-induced hepatitis. J Hepatol. 2010; 53: 1059-1068. doi: 10.1016/j.jhep.2010.05.029 PMID: 20813418
31. Jacobs M, Brown N, Allie N, Ryffel B. Fatal Mycobacterium bovis BCG infection in TNF-LT-alpha-deficient mice. Clin Immunol. 2000; 94: 192-199. PMID: 10692238
32. Gresnigt MS, Rosler B, Jacobs CW, Becker KL, Joosten LA, et al. The IL-36 receptor pathway regulates Aspergillus fumigatus-induced Th1 and Th17 responses. Eur J Immunol. 2013; 43: 416-426. doi: 10.1002/eji.201242711 PMID: 23147407
33. Bachmann M, Scheiermann P, Hardle L, Pfeilschifter J, Muhl H. IL-36gamma/IL-1F9, an innate T-bet target in myeloid cells. J Biol Chem. 2012; 287: 41684-41696. doi: 10.1074/jbc.M112.385443 PMID: 23095752
34. Chustz RT, Nagarkar DR, Poposki JA, Favoreto S Jr, Avila PC, et al. Regulation and function of the IL-1 family cytokine IL-1F9 in human bronchial epithelial cells. Am J Respir Cell Mol Biol. 2011; 45: 145-153. doi: 10.1165/rcmb.2010-0075OC PMID: 20870894
35. Parsanejad R, Fields WR, Steichen TJ, Bombick BR, Doolittle DJ. Distinct regulatory profiles of interleukins and chemokines in response to cigarette smoke condensate in normal human bronchial epithelial (NHBE) cells. J Interferon Cytokine Res. 2008; 28: 703-712. doi: 10.1089/jir.2008.0139 PMID: 18937544
36. Vos JB, van Sterkenburg MA, Rabe KF, Schalkwijk J, Hiemstra PS, et al. Transcriptional response of bronchial epithelial cells to Pseudomonas aeruginosa: identification of early mediators of host defense. Physiol Genomics. 2005; 21: 324-336. PMID: 15701729
37. Bochkov YA, Hanson KM, Keles S, Brockman-Schneider RA, Jarjour NN, et al. Rhinovirus-induced modulation of gene expression in bronchial epithelial cells from subjects with asthma. Mucosal Immunol. 2010; 3: 69-80. doi: 10.1038/mi.2009.109 PMID: 19710636
38. Fremond CM, Yeremeev V, Nicolle DM, Jacobs M, Quesniaux VF, et al. Fatal Mycobacterium tuberculosis infection despite adaptive immune response in the absence of MyD88. J Clin Invest. 2004; 114:1790-1799. PMID: 15599404
39. Mayer-Barber KD, Andrade BB, Oland SD, Amaral EP, Barber DL, et al. Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk. Nature. 2014; 511: 99-103. doi: 10.1038/nature13489 PMID: 24990750
40. Blumberg H, Dinh H, Dean C Jr, Trueblood ES, Bailey K, et al. IL-1RL2 and its ligands contribute to the cytokine network in psoriasis. J Immunol. 2010; 185: 4354-4362. doi: 10.4049/jimmunol.1000313 PMID: 20833839
41. Tortola L, Rosenwald E, Abel B, Blumberg H, Schafer M, et al. Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk. J Clin Invest. 2012; 122: 3965-3976. doi: 10.1172/JCI63451 PMID: 23064362
42. Olleros ML, Vesin D, Lambou AF, Janssens JP, Ryffel B, et al. Dominant-negative tumor necrosis factor protects from Mycobacterium bovis Bacillus Calmette Guerin (BCG) and endotoxin-induced liver injury without compromising host immunity to BCG and Mycobacterium tuberculosis. J Infect Dis. 2009; 199: 1053-1063. doi: 10.1086/597204 PMID: 19222369
43. Dietrich D, Gabay C. Inflammation: IL-36 has proinflammatory effects in skin but not in joints. Nat Rev Rheumatol. 2014; 10: 639-640. doi: 10.1038/nrrheum.2014.156 PMID: 25201385